We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Prothrombin Time Derived from POC Test Compared to Laboratory Test

By LabMedica International staff writers
Posted on 17 Feb 2015
Prothrombin time/international normalized ratio (PT/INR) is used for dosing and monitoring oral anticoagulant therapy (OAT) based on warfarin, as the therapeutic range of warfarin is narrow and there is a considerable variation in inter- and intra-individual pharmacologic response.

One of the most widely used point-of-care (POC) devices to evaluate prothrombin time for monitoring oral anticoagulant therapy is unlike other laboratory methods, as it detects electrical signals produced by thrombin activity to derive the international normalized ratio (INR). More...


Scientists at Yonsei University College of Medicine (Seoul, Korea) collected 91 venous blood samples submitted for fibrinogen testing to the clinical laboratory. Platelet-poor plasma was obtained by centrifugation. The fibrinogen level was measured using Fibrinogen-C XL reagent (Instrumentation Laboratory; Milan, Italy) via Clauss method using ACL TOP (Beckman Coulter; Fullerton, CA, USA). Samples were selected after fibrinogen testing according to the fibrinogen level. PT INR was measured by both the laboratory method and CoaguChek XS (Roche Diagnostics; Mannheim, Germany).

The samples were stratified into low, mid, and high fibrinogen groups by fibrinogen levels of <130 mg/dL, 130–450 mg/dL, and >450 mg/dL, respectively. The mean INR difference of the low fibrinogen group was significantly different from that of the mid or high fibrinogen group. In the low fibrinogen group, CoaguChek XS INR showed a negative bias compared with the laboratory INR, while the mid and high fibrinogen groups had positive bias.

The authors concluded that that patient selection according to fibrinogen status should precede the implementation of POC testing using CoaguChek XS. Also, periodic comparisons between CoaguChek XS and laboratory INR results should be continued during the use of CoaguChek XS. The study was published on January 31, 2015, in the Journal of Clinical Laboratory Analysis.

Related Links:

Yonsei University College of Medicine
Instrumentation Laboratory
Roche Diagnostics



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.